ADVERTISEMENT
Shire Says ADHD Drug Meets Main Goal of Study
By Reuters Staff
(Reuters) - Irish drugmaker Shire Plc said a study testing an experimental drug to treat attention-deficit disorder met the main goal, bringing the drug one step closer to approval in the United States.
Shire, which sells Vynase (lisdexamfetamine) and Intuniv (guanfacine) to treat attention-deficit/hyperactivity disorder (ADHD), has focused on developing treatments for the condition that affects about 4 percent of the U.S. population.
Data showed both doses of the experimental drug, SHP465, were better than a placebo in treating patients with ADHD, Shire said.
The company said it was on track to get the drug approved by the U.S. Food and Drug Administration in the second half of 2017.
(c) Copyright Thomson Reuters 2016. Click For Restrictions - https://about.reuters.com/fulllegal.asp
